Serum Dickopff 1 as a Novel Biomarker in Hepatocellular Carcinoma Diagnosis and Follow Up After Ablative Therapy
Received 6 June 2019
Accepted for publication 30 October 2019
Published 17 December 2019 Volume 2019:11 Pages 10555—10562
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 3
Editor who approved publication: Dr Antonella D'Anneo
Yehia Sadek Younis,1 Hatem Samir Alegaily,1 Waleed Elagawy,2 Atteyat Aboelmaged Semeya,3 Yousry Esam-Eldin Abo-Amer,3 Mohamed El-Abgeegy,4 Sahar Mohamed Mostafa,4 Heba Fadl Elsergany,4 Sherief Abd-Elsalam5
1Hepatology, Gastroenterology and Infectious Diseases, Benha Faculty of Medicine, Qalybia, Egypt; 2Department of Tropical Medicine, Faculty of Medicine, Port Said University, Port Fouad, Egypt; 3Hepatology, Gastroenterology and Infectious Diseases, Mahala Hepatology Teaching Hospital, Gharbia, Egypt; 4National Hepatology and Tropical Medicine Research Institute, Cairo, Egypt; 5Department of Tropical Medicine, Faculty of Medicine, Tanta University, Gharbia, Egypt
Correspondence: Sherief Abd-Elsalam
Department of Tropical Medicine, Faculty of Medicine, Tanta University, El-Geish Street, Tanta, Egypt
Background: This study aimed to evaluate the role of Dickopff 1 (DKK1) serum levels as a marker for early detection of hepatocellular carcinoma (HCC) and to compare it with alphafetoprotein (AFP) after non-surgical intervention (microwave ablation, radiofrequency ablation) in HCC.
Patients and methods: This prospective study was conducted in Al-Mahalla hepatology teaching hospital from June 2015 to June 2017. One hundred and twenty patients were included. They were classified into four groups: Group A: 40 patients with chronic liver disease; Group B: 40 patients with HCC which were divided into 2 main sub groups, group Ba which included HCC patients who were not eligible for ablative therapy and group Bb which included HCC patients who were eligible for ablative therapy; Group C: 20 healthy control subjects matched for age and sex; Group D: 20 HCC patients with negative AFP, DKK1 was done for them.
Results: There was a highly significant difference (p < 0.001) between groups regarding serum level of Dickpoff 1 with mean of 1 ng/mL in group A (cirrhotic), 2.38 ng/mL in group B (HCC), and 1.83 ng/mL in group D (AFP negative HCC) in comparison to control group C with mean of 0.54 ng/mL. There was a highly statistically significant difference (p value less =0.01) in the studied groups regarding serum Dickpoff 1 before and after intervention with a mean of 2.38 ng/mL before intervention and mean of 1.37 ng/mL after 1 month of intervention.
Conclusion: Serum Dkk-1 has higher sensitivity, specificity, and accuracy in early diagnosis of HCC than AFP.
Keywords: serum Dickopff 1, aphafeto protein, hepatocellular carcinoma, radiofrequency ablation, microwave ablation, TACE
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]